CP 283097

Drug Profile

CP 283097

Latest Information Update: 17 Apr 2012

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Pfizer
  • Class Antiepileptic drugs; Neuroprotectants
  • Mechanism of Action NR2B N-Methyl-D-Aspartate antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Migraine; Neurodegenerative disorders

Most Recent Events

  • 31 Jul 2005 Discontinued - Preclinical for Migraine in USA (unspecified route)
  • 31 Jul 2005 Discontinued - Preclinical for Neurodegenerative disorders in USA (unspecified route)
  • 23 Jun 2000 Pfizer has merged with Warner-Lambert
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top